sayacare_log

Hey, User !

Select delivery location

Fill in New Patient Details

Welcome to SayaCare- India's only E-pharmacy that Tests every Batch👋FREE delivery on 1st order — Use coupon: TESTME101

sayacare_logosayacare_logo

Repaglinide 0.5 mg + Voglibose 0.3 mg

Testeddrug image
Testeddrug image
Testeddrug image
Testeddrug image
Testeddrug image

Repaglinide 0.5 mg + Voglibose 0.3 mg

Rx Required

Drug Code: 2464

Rx Required
| tablettablet| Pack of 10 tablets
MRP ₹136.87

₹43

68% off

🔥110 People bought recently

Per unit price

₹ 4.3/tablets

Quality Lab Tested

This batch has been verified!

WHO- GMP

Sourced Medicines

Each Batch Tested

by SayaCare at Govt. Certified NABL

1,00,000+

Trusted customers

Batch Details

Composition

repaglinide 0.5 mg + voglibose 0.3 mg

Batch

17|MHT260085A

Expiry

March 2028

Brands with same SaltBut mostly higher prices

volibo r 0.3

₹ 1555

volibo r 0.3

₹ 1555

volibo r 0.3

₹ 1555

vogli rapid 0.3 tablet

₹ 148

vobit r 0.3+0.5

₹ 157

voglirapid

₹ 118

eurepa v 05 03 tablet

₹ 128

voglinorm r tablet

₹ 128

volga r 05mg 03mg tablet

₹ 90

vogolist r

₹ 150

Why Choose SayaCare ?

You pay for the medicine, not the brand name

Same active ingredients

Exact Same Dosage Type

Lab Tested Quality

Transparent Test Report

Batch Details

Composition

repaglinide 0.5 mg + voglibose 0.3 mg

Batch

17|MHT260085A

Expiry

March 2028

Medicine Highlights

Uses 1. To manage type 2 Diabetes mellitus.
Common Side Effects  1. Low blood sugar
2. Infection in the nose or throat, sore throat 
3. Headache 
4. Stuffy or runny nose 
5. Joint pain 
6. Nausea 
7. Diarrhea 
8. Back pain 
9. Abdominal or stomach discomfort  
10. Cough or hoarseness  
11. Decreased appetite  
12. Diarrhea  
13. Fast or shallow breathing  
14. Fever or chills  
15. General feeling of discomfort  
15. Lower back or side pain  
16. Muscle pain or cramping  
17. Painful or difficult urination  
18. Sleepiness 
Additional Information 1. Take this medication 15 to 30 minutes before meals to get a good effect.
Storage 1. The medicine should be stored at room temperature.
2. Keep away from sunlight and moisture.
3. Keep away from the reach of children
How to Take This MedicineSwallow this medicine with water. 

Repaglinide + Voglibose Uses

Repaglinide 0.5 mg + voglibose 0.3 mg is an oral medicine belonging to the category of antidiabetic drugs and is used for the management of type 2 diabetes mellitus.

Repaglinide + Voglibose side effects

More Common  

  1. Low blood sugar (see below) 
  2. Infection in the nose or throat, sore throat 
  3. Headache 
  4. Stuffy or runny nose 
  5. Joint pain 
  6. Nausea 
  7. Diarrhea 
  8. Back pain 
  9. Cough or hoarseness  
  10. Decreased appetite  
  11. Diarrhea  
  12. Fast or shallow breathing  
  13. Fever or chills  
  14. General feeling of discomfort  
  15. Lower back or side pain  
  16. Muscle pain or cramping  
  17. Painful or difficult urination  
  18. Sleepiness 

Less Common 

  1. Breathing problems or wheezing 
  2. Racing heart 
  3. Fever or general ill feeling 
  4. Swollen lymph nodes 
  5. Swelling of the face, lips, mouth, tongue, or throat 
  6. Trouble swallowing or throat tightness 
  7. Itching, skin rash, or pale red bumps on the skin called hives 
  8. Nausea or vomiting 
  9. Dizziness, feeling lightheaded, or fainting 
  10. Stomach cramps 
  11. Joint pain 
  12. Suicidal thoughts 
  13. Hallucinations 
  14. Headache 
  15. Crankiness or anxiety 
  16. Hunger 
  17. Dizziness or confusion 
  18. Blurry vision 
  19. Slurred speech 
  20. Sweating 
  21. Feeling jittery or shakiness 
  22. Fast heartbeat 
  23. Seizures 
  24. Anxiety 
  25. Blurred vision 
  26. Chest discomfort 
  27. Cold sweats 
  28. Coma 
  29. Confusion 
  30. Cool, pale skin 
  31. Depression 
  32. Difficult or labored breathing 
  33. Dizziness 
  34. Fast, irregular, pounding, or racing heartbeat or pulse 
  35. Feeling of warmth 
  36. Headache 
  37. Increased hunger 
  38. Increased sweating 
  39. Nausea 
  40. Nervousness 
  41. Nightmares 
  42. Redness of the face, neck, arms, and occasionally, upper chest 
  43. Shakiness 
  44. Slurred speech 
  45. Tightness in the chest 
  46. Unusual tiredness or weakness 

How Repaglinide + Voglibose works

Repaglinide and voglibose work by lowering blood sugar in two ways: repaglinide makes the pancreas release insulin quickly after meals to handle sudden sugar spikes, while voglibose reduces extra sugar production by the liver and helps muscles use insulin better; together, they control both mealtime surges and background sugar levels.

Safety Measures and Warning

Pregnancy

Due to a lack of studies on the effects of repaglinide and voglibose on the fetus during pregnancy, its safety is not clearly established. Therefore, if you are pregnant or planning to conceive, inform your doctor.

Breastfeeding

Repaglinide and voglibose pass into breast milk. Tell your healthcare provider if you are breastfeeding or plan to breastfeed. Your healthcare provider will advise you if you should stop breastfeeding or stop repaglinide.

Kidney and Liver Problems

Patients suffering from kidney and liver problems are more prone to kidney and liver damage, as the drug is made into a less toxic form in the liver and kidney, leading to strain on the liver and kidney, causing toxicity, so consult a doctor before using it.

Repaglinide + Voglibose Interaction with Food Product

Avoid alcohol and smoking while on Repaglinide and Voglibose , as they strain the liver and pancreas and can disturb blood sugar control, sometimes raising it, sometimes lowering it.

Repaglinide + Voglibose Interaction with Other Medicines

Avoid taking Repaglinide 0.5 mg + Voglibose 0.3 mg with the following medicines, as it may increase or decrease the desired effect, or in worse cases, it could be fatal:

Repaglinide + Voglibose Chemical Structure

IUPAC (International Union of Pure and Applied Chemistry)/ Chemical name

Repaglinide-2-ethoxy-4-[2-[3-methyl -1-[2-(1-piperidinyl)phenyl]butyl]amino] benzoic acid

Voglibose- (1S,2S,3R,4S,5S) -5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol

Intake routine/cycle

Daily dose

Take repaglinide and voglibose exactly as your doctor recommends. The dose may change based on your condition and how well you respond. Do not take more than prescribed without consulting your doctor.

Missed Dose

If you forget to take your medicine, take the medication as soon as you remember. If it’s nearly time for your next dose, skip the missed one and continue with your regular schedule. Always consult the doctor before making any changes to your dosage.

Overdose

It is not recommended to take more than 3 tablets of 0.50 mg of repaglinide and 0.3 mg of voglibose per day, as it may cause severe overdosing effects like extreme drowsiness, confusion, low blood pressure, unconsciousness, sweating, and seizures. Immediately give the person fruit or glucose-containing liquids and sugary foods to minimize the effects. If you face any of the severe effects, seek medical help.

Storage

  1. Store the medicine at room temperature. 
  2. Keep away from sunlight and moisture. 
  3. Keep out of reach of children. 

Directions for use

  1. Take repaglinide and voglibose exactly as prescribed by your doctor, at the same time each day. 
  2. Do not stop taking repaglinide and voglibose without your doctor’s approval, even if you feel better. 
  3. If you forget to take repaglinide and voglibose, take them as soon as you remember. If it’s almost time for your next dose, skip the missed dose. 

Repaglinide + Voglibose Summary

Repaglinide and voglibose are oral diabetes medicines that work together to control blood sugar after meals. Repaglinide prompts quick insulin release from the pancreas, while voglibose slows sugar absorption in the gut; like one opens the insulin tap, the other closes the sugar absorption gate. Taken before meals, they help prevent sugar spikes but may cause gas or low sugar if meals are skipped. Alcohol and heavy carbs can worsen side effects. Patients with type 1 diabetes, diabetic ketoacidosis, or those taking gemfibrozil, should avoid taking this medication. Taking more than 2 mg of this medicine can cause severe overdosing effects like extreme drowsiness, confusion, low blood pressure, unconsciousness, sweating, and seizures.

FAQ’s

What is the mechanism of action of repaglinide?

Repaglinide is an antidiabetic medicine used to control high blood glucose levels, and it acts by stimulating the pancreas to stimulate more insulin that controls the blood sugar levels

What is the drug class of repaglinide?

Repaglinide belongs to the category of meglitinides, the antidiabetic drugs used to control blood glucose levels in the body effectively immediately after a meal.

What are the uses of Voglibose 250 mg?

Voglibose 250 mg is a medicine belonging to the biguanides and used to control blood glucose levels and sometimes used in females for polycystic ovarian syndrome.

What is the drug class of the Voglibose tablet?

Voglibose belongs to the class of biguanides used to treat diabetes and control blood sugar levels.

What is the mechanism of action of Voglibose Tablets?

Voglibose lowers blood sugar mainly by reducing glucose production in the liver and improving insulin sensitivity in muscles and fat, helping the body use sugar more effectively. It does this by activating the cell’s energy sensor AMPK, which shifts the body into a “use fuel wisely” mode without causing low sugar.

Reference

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 65981, Repaglinide. Internet. Bethesda (MD): National Library of Medicine (US); [cited 0.0.3.55 Jul 5]. Available from. 
  2. Drug Bank Online. Repaglinide [Internet]. Edmonton (AB): Canadian Institutes of Health Research; [cited 0.0.3.55 Jul 5]. Available from. 
  3. Mawhinney S, Gaddey HL. Repaglinide. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 0.0.3.53 Jan– [cited 0.0.3.55 Jul 5]. Available from. 
  4. WebMD. Repaglinide oral: Uses, side effects, interactions, pictures, warningsand dosing [Internet]. New York (NY): WebMD LLC; [cited 0.0.3.55 Jul 5]. Available from. 
  5. Drugs.com. Repaglinide Monograph [Internet]. Auckland (NZ): Data pharm; [cited 0.0.3.55 Jul 5]. Available from. 
  6. Bailey CJ. voglibose: effects on micro and macrovascular complications in type 2 diabetes. Br J Diabetes Vasc Dis. 2008;8(3):121–7. Available from. 
  7. Drugs.com. Voglibose [Internet]. Drugs.com International. [cited 2025 Aug 14]. Available from. 
  8. DrugBank Online. Voglibose [Internet]. Edmonton (AB): DrugBank; [cited 2025 Aug 14]. Available from. 
  9. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 10th ed. Philadelphia: Elsevier; 2017. Chapter 25, The Endocrine System [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); [cited 2025 Aug 14]. Available from. 

Siva Krishna Adithya Bhumireddy avatar

Written By-

Siva Krishna Adithya Bhumireddy

Medical content writer

Bachelors in Pharmacy | 1+ Year experience

Mahak Phartyal avatar

Reviewed By-

Mahak Phartyal

Medical Content writer and reviewer

Bachelors in Pharmacy | 2+ Year experience

Last Updated: 07 Apr 2026

Similar Items

India's OnlyE- Pharmacy
That Tests Every Medicine Batch.

Tested hai, Toh bharosa hai!

Safe medicines

-Rigorously Tested-

Quality Reports

-Full Transparency-

Low Prices

-Save up to 80%-

Home Delivery

-Fast & Reliable-

Disclaimer

All brand names, trademarks, trade dress, logos, and product names of third parties appearing on SayaCare are the property of their respective owners and are protected under applicable intellectual property laws, including the Trade Marks Act, 1999. SayaCare claims no ownership over, or association with, any such third-party intellectual property.

Third-party brand names and trademarks are referenced on this platform for the purposes of product identification and to assist users in locating generic or equivalent alternatives, in accordance with honest commercial practices under the Trade Marks Act, 1999. Such references do not form part of SayaCare's own branding or promotional identity.

SayaCare is an independent platform and is not affiliated with, endorsed by, sponsored by, or acting as an authorised agent or distributor of any brand referenced herein, and makes no such representation to consumers. The appearance of any brand name on this platform does not imply any formal partnership, endorsement, or direct commercial relationship with the respective brand owner.

Where SayaCare provides information on the generic equivalence of any product to a branded medicine, such information is based on publicly available regulatory data, including schedules under the Drugs and Cosmetics Act, 1940, and information published by the CDSCO. Any editorial content, ratings, or commentary represents the independent views of the platform and should not be attributed to any third-party brand. Neither should be construed as a statement regarding a brand's overall performance or reputation.

All information on this platform is for general awareness only and does not constitute medical advice. Users are strongly advised to consult a registered medical practitioner or licensed pharmacist before substituting any branded medicine with a generic alternative or acting on any information available here. SayaCare is not responsible for brand references or opinions expressed by users in reviews or uploaded content, which represent the views of individual users alone. Users are prohibited from uploading content that infringes the intellectual property rights of any third party.

SayaCare respects the intellectual property rights of all brand owners and does not intend to infringe upon any trademark, trade dress, or related right. If you believe any content on this platform infringes your rights, please contact our IP Grievance Officer at [email protected] . All bona fide complaints will be reviewed within 7 business days and appropriate remedial action taken where infringement is established. This mechanism is maintained in accordance with the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021.